Clinical Trials
26 trialsNCT03932409 2026-05-08
FIERCE
University of Oklahoma
Phase 1 Active not recruiting
NCT03537690 2026-04-29
FID-007 in Treating Participants With Advanced Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT01281176 2026-04-20
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05307705 2026-04-20
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04220827 2026-04-15
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05017012 2026-03-27
MK-3475A-C18
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT03044613 2026-03-23
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06883630 2026-03-05
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
RemeGen Co., Ltd.
Phase 1 Active not recruiting
NCT03233139 2026-02-12
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT04391049 2026-01-30
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Phase 1 Active not recruiting
NCT02213497 2026-01-08
Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Active not recruiting
NCT05276973 2025-12-19
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT06107868 2025-12-08
GyneRep
University Health Network, Toronto
Phase 1 Active not recruiting
NCT05117476 2025-11-24
MICA
Cullinan Therapeutics Inc.
Phase 1 Active not recruiting
NCT06328738 2025-11-19
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
Phase 1 Active not recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT03716180 2025-09-22
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02608216 2025-09-03
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
University of Pennsylvania
Phase 1 Active not recruiting
NCT03858322 2025-08-11
'ADVANCE' (A Pilot Trial)
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT04046575 2025-07-11
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting